Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 7/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.44 |
| ▸ | UNG | P13051 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22098249 | 0.95 | CYP4F2 (0.50) | CYP4F2CYP4A11MAOAMAOBUNG | |
| SCHEMBL2140044 | 0.89 | CYP4F2 (0.53) | CYP4F2CYP4A11MAOAMAOBUNG | |
| SCHEMBL32066891 | 0.89 | CYP4F2 (0.53) | CYP4F2CYP4A11MAOAMAOBUNG | |
| SCHEMBL8205516 | 0.82 | ALDH1A1 (0.59) | CYP4F2CYP4A11MAOAMAOBALDH1A1 | |
| SCHEMBL23648072 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1TBXA2RPLAU | |
| SCHEMBL3032724 | 0.81 | HDAC4 (0.47) | MAOAMAOBALDH1A1 | |
| SCHEMBL10490702 | 0.81 | MAOA (0.47) | MAOAMAOBUNGALDH1A1FFAR1 | |
| SCHEMBL27799506 | 0.81 | MAOA (0.44) | CYP4F2CYP4A11MAOAMAOBUNG | |
| SCHEMBL9480031 | 0.81 | MAOA (0.51) | MAOAMAOBUNGALDH1A1FFAR1 | |
| SCHEMBL9559961 | 0.81 | MAOA (0.51) | MAOAMAOBUNGALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563784-B2 | Catalytic method of manufacture of compounds of the diol type | RHODIA POLIAMIDA E ESPECIALIDADES LTDA (BR) | 2013-10-22 | — | — | US | claimed |
| US-20110313204-A1 | CATALYTIC METHOD OF MANUFACTURE OF COMPOUNDS OF THE DIOL TYPE | RHODIA POLIAMIDA E ESPECIALIDADES LTDA (BR) | 2011-12-22 | — | — | US | claimed |
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| CN-102625808-B | Spirocyclic amide derivatives | ASTRAZENECA AB | 2014-08-27 | — | — | CN | disclosed |
| US-8563784-B2 | Catalytic method of manufacture of compounds of the diol type | RHODIA POLIAMIDA E ESPECIALIDADES LTDA (BR) | 2013-10-22 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| CN-102625808-A | Spirocyclic amide derivatives | ASTRAZENECA AB | 2012-08-01 | — | — | CN | disclosed |
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| US-20110313204-A1 | CATALYTIC METHOD OF MANUFACTURE OF COMPOUNDS OF THE DIOL TYPE | RHODIA POLIAMIDA E ESPECIALIDADES LTDA (BR) | 2011-12-22 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313204-A1 | CATALYTIC METHOD OF MANUFACTURE OF COMPOUNDS OF THE DIOL TYPE | ADH1C, ADH1A, AGL | CYP4F2 304/4885CYP4A11 129/4885MAOA 222/4885 |
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CYP4F2 874/4885CYP4A11 252/4885MAOA 560/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CYP4F2 874/4885CYP4A11 252/4885MAOA 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.